A citation-based method for searching scientific literature

Lennart Christopher Schiwy, Caroline Garcia Forlim, Djo Juliette Fischer, Simone Kühn, Maxi Becker, Jürgen Gallinat. Schizophr Res 2022
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones.
Felice Iasevoli, Sara Giordano, Raffaele Balletta, Gianmarco Latte, Maria Vittoria Formato, Emiliano Prinzivalli, Domenico De Berardis, Carmine Tomasetti, Andrea de Bartolomeis. Prog Neuropsychopharmacol Biol Psychiatry 2016
77
50

Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study.
Theresa Wimberley, Henrik Støvring, Holger J Sørensen, Henriette T Horsdal, James H MacCabe, Christiane Gasse. Lancet Psychiatry 2016
80
50

Predictive value of thought disorder in new-onset psychosis.
James Wilcox, George Winokur, Ming Tsuang. Compr Psychiatry 2012
30
50


Treatment resistant schizophrenia and neurological soft signs may converge on the same pathology: Evidence from explanatory analysis on clinical, psychopathological, and cognitive variables.
Andrea de Bartolomeis, Emiliano Prinzivalli, Gemma Callovini, Luigi D'Ambrosio, Benedetta Altavilla, Camilla Avagliano, Felice Iasevoli. Prog Neuropsychopharmacol Biol Psychiatry 2018
20
50

The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.
Richard S E Keefe, Terry E Goldberg, Philip D Harvey, James M Gold, Margaret P Poe, Leigh Coughenour. Schizophr Res 2004
921
50

Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses.
J Lally, O Ajnakina, M Di Forti, A Trotta, A Demjaha, A Kolliakou, V Mondelli, T Reis Marques, C Pariante, P Dazzan,[...]. Psychol Med 2016
148
50

Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.
Oliver D Howes, Rob McCutcheon, Ofer Agid, Andrea de Bartolomeis, Nico J M van Beveren, Michael L Birnbaum, Michael A P Bloomfield, Rodrigo A Bressan, Robert W Buchanan, William T Carpenter,[...]. Am J Psychiatry 2017
425
50


The association between season of birth, age at onset, and clozapine use in schizophrenia.
J S Kim, C M Park, J A Choi, E Park, H J Tchoe, M Choi, J K Suh, Y H Kim, S H Won, Y C Chung,[...]. Acta Psychiatr Scand 2017
7
50

Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance.
H Y Meltzer, J Rabinowitz, M A Lee, P A Cola, R Ranjan, R L Findling, P A Thompson. Am J Psychiatry 1997
122
50

A rating scale for the assessment of objective and subjective formal Thought and Language Disorder (TALD).
Tilo Kircher, Axel Krug, Mirjam Stratmann, Sayed Ghazi, Christian Schales, Michael Frauenheim, Lena Turner, Paul Fährmann, Tobias Hornig, Michael Katzev,[...]. Schizophr Res 2014
49
50

Disorganization/cognitive and negative symptom dimensions in the at-risk mental state predict subsequent transition to psychosis.
Arsime Demjaha, Lucia Valmaggia, Daniel Stahl, Majella Byrne, Philip McGuire. Schizophr Bull 2012
136
50

Clozapine: Why Is It So Uniquely Effective in the Treatment of a Range of Neuropsychiatric Disorders?
Dara Gammon, Catherine Cheng, Anna Volkovinskaia, Glen B Baker, Serdar M Dursun. Biomolecules 2021
7
50

Disease Severity in Treatment Resistant Schizophrenia Patients Is Mainly Affected by Negative Symptoms, Which Mediate the Effects of Cognitive Dysfunctions and Neurological Soft Signs.
Felice Iasevoli, Camilla Avagliano, Benedetta Altavilla, Annarita Barone, Luigi D'Ambrosio, Marta Matrone, Danilo Notar Francesco, Eugenio Razzino, Andrea de Bartolomeis. Front Psychiatry 2018
16
50

Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study.
Alp Üçok, Ugur Çıkrıkçılı, Ceylan Ergül, Öznur Tabak, Ada Salaj, Sercan Karabulut, Christoph U Correll. CNS Drugs 2016
8
50


An association between autumn birth and clozapine treatment in patients with schizophrenia: a population-based analysis.
Holger J Sørensen, Leslie Foldager, Rasmus Røge, Sofie Gry Pristed, Jesper T Andreasen, Jimmi Nielsen. Nord J Psychiatry 2014
5
50


Sheltered employment in schizophrenia is related to disorganization symptoms, processing speed and metaphor comprehension.
Artur Daren, Przemysław Adamczyk, Piotr Błądziński, Aleksandra Sułecka-Stelmach, Anna Starowicz-Filip, Łukasz Gawęda, Aneta Kalisz, Andrzej Cechnicki. Psychiatr Pol 2020
1
100

Disorganization and reality distortion in schizophrenia: a meta-analysis of the relationship between positive symptoms and neurocognitive deficits.
Joseph Ventura, April D Thames, Rachel C Wood, Lisa H Guzik, Gerhard S Hellemann. Schizophr Res 2010
106
50

Hippocampus and cognitive domain deficits in treatment-resistant schizophrenia: A comparison with matched treatment-responsive patients and healthy controls✰,✰✰,★,★★.
Junchao Huang, Yu Zhu, Fengmei Fan, Song Chen, Yuan Hong, Yimin Cui, Xingguang Luo, Shuping Tan, Zhiren Wang, Lan Shang,[...]. Psychiatry Res Neuroimaging 2020
11
50

Profiling cognitive impairment in treatment-resistant schizophrenia patients.
Dorota Frydecka, Jan Aleksander Beszłej, Piotr Gościmski, Andrzej Kiejna, Błażej Misiak. Psychiatry Res 2016
50
50

Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors.
A Demjaha, J M Lappin, D Stahl, M X Patel, J H MacCabe, O D Howes, M Heslin, U A Reininghaus, K Donoghue, B Lomas,[...]. Psychol Med 2017
133
50

The dysconnection hypothesis (2016).
Karl Friston, Harriet R Brown, Jakob Siemerkus, Klaas E Stephan. Schizophr Res 2016
269
50

Clinical evaluation of functional capacity in treatment resistant schizophrenia patients: Comparison and differences with non-resistant schizophrenia patients.
Felice Iasevoli, Luigi D'Ambrosio, Danilo Notar Francesco, Eugenio Razzino, Elisabetta Filomena Buonaguro, Sara Giordano, Thomas L Patterson, Andrea de Bartolomeis. Schizophr Res 2018
11
50

Formal thought disorders: from phenomenology to neurobiology.
Tilo Kircher, Henrike Bröhl, Felicitas Meier, Jennifer Engelen. Lancet Psychiatry 2018
55
50

Age at onset in subtypes of schizophrenic disorders.
S Beratis, J Gabriel, S Hoidas. Schizophr Bull 1994
64
50

Linking the PANSS, BPRS, and CGI: clinical implications.
Stefan Leucht, John M Kane, Eva Etschel, Werner Kissling, Johannes Hamann, Rolf R Engel. Neuropsychopharmacology 2006
217
50

The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research.
Steven G Potkin, John M Kane, Christoph U Correll, Jean-Pierre Lindenmayer, Ofer Agid, Stephen R Marder, Mark Olfson, Oliver D Howes. NPJ Schizophr 2020
89
50

Clinical management of negative symptoms of schizophrenia: An update.
Evangelia M Tsapakis, Trisevgeni Dimopoulou, Frank I Tarazi. Pharmacol Ther 2015
40
50

Relationships between early age at onset of psychotic symptoms and treatment resistant schizophrenia.
Felice Iasevoli, Eugenio Razzino, Benedetta Altavilla, Camilla Avagliano, Annarita Barone, Mariateresa Ciccarelli, Luigi D'Ambrosio, Marta Matrone, Federica Milandri, Danilo Notar Francesco,[...]. Early Interv Psychiatry 2022
7
50


Schizophrenic syndromes associated with treatment response.
M J Cuesta, V Peralta, J de Leon. Prog Neuropsychopharmacol Biol Psychiatry 1994
20
50

Mental planning and the Tower of London task.
L H Phillips, V E Wynn, S McPherson, K J Gilhooly. Q J Exp Psychol A 2001
72
50

The positive and negative syndrome scale (PANSS) for schizophrenia.
S R Kay, A Fiszbein, L A Opler. Schizophr Bull 1987
50



The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model.
Mark van der Gaag, Tonko Hoffman, Mila Remijsen, Ron Hijman, Lieuwe de Haan, Berno van Meijel, Peter N van Harten, Lucia Valmaggia, Marc de Hert, Anke Cuijpers,[...]. Schizophr Res 2006
363
50

Neuropsychological function at first episode in treatment-resistant psychosis: findings from the ÆSOP-10 study.
Eugenia Kravariti, Arsime Demjaha, Jolanta Zanelli, Fowzia Ibrahim, Catherine Wise, James H MacCabe, Abraham Reichenberg, Izabela Pilecka, Kevin Morgan, Paul Fearon,[...]. Psychol Med 2019
18
50

A symptom combination predicting treatment-resistant schizophrenia - A strategy for real-world clinical practice.
Bruno B Ortiz, Cinthia H Higuchi, Cristiano Noto, Dan W Joyce, Christoph U Correll, Rodrigo A Bressan, Ary Gadelha. Schizophr Res 2020
7
50

Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
Jean-Pierre Lindenmayer, Pal Czobor, Jan Volavka, Jeffrey A Lieberman, Leslie Citrome, Brian Sheitman, Joseph P McEvoy, Thomas B Cooper, Miranda Chakos. J Clin Psychiatry 2004
50
50

International consensus study of antipsychotic dosing.
David M Gardner, Andrea L Murphy, Heather O'Donnell, Franca Centorrino, Ross J Baldessarini. Am J Psychiatry 2010
876
50


Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification.
Saeed Farooq, Ofer Agid, George Foussias, Gary Remington. Schizophr Bull 2013
52
50

Tobacco smoking in treatment-resistant schizophrenia patients is associated with impaired cognitive functioning, more severe negative symptoms, and poorer social adjustment.
Felice Iasevoli, Raffaele Balletta, Valentina Gilardi, Sara Giordano, Andrea de Bartolomeis. Neuropsychiatr Dis Treat 2013
40
50

Genome-wide association study of clinical dimensions of schizophrenia: polygenic effect on disorganized symptoms.
Ayman H Fanous, Baiyu Zhou, Steven H Aggen, Sarah E Bergen, Richard L Amdur, Jubao Duan, Alan R Sanders, Jianxin Shi, Bryan J Mowry, Ann Olincy,[...]. Am J Psychiatry 2012
86
50


Cognitive Deficits in Psychotic Disorders: A Lifespan Perspective.
Julia M Sheffield, Nicole R Karcher, Deanna M Barch. Neuropsychol Rev 2018
147
50

Disrupted functional connectivity with dopaminergic midbrain in cocaine abusers.
Dardo Tomasi, Nora D Volkow, Ruiliang Wang, Jean H Carrillo, Thomas Maloney, Nelly Alia-Klein, Patricia A Woicik, Frank Telang, Rita Z Goldstein. PLoS One 2010
90
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.